1-2 of 2
Andrew T Stefka
Close
Sort by
Journal Articles

Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Tadeusz Kubicki, Dominik Dytfeld, Tomasz Wrobel, Krzysztof Jamroziak, Pawel Robak, Jaroslaw Czyz, Agata Tyczynska, Agnieszka Druzd-Sitek, Krzysztof Giannopoulos, Adam Nowicki, Tomasz Szczepaniak, Anna Lojko-Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Michal Pula, Justyna Rybka, Maciej Majcherek, Lidia Usnarska-Zubkiewicz, Lukasz Szukalski, Agnieszka Konska, Jan M. Zaucha, Jan Walewski, Damian Mikulski, Olga Czabak, Tadeusz Robak, Dorota Kruk-Kwapisz, Oscar Boutros Lahoud, Jeffrey A. Zonder, Kent Griffith, Andrew T Stefka, Ken Jiang, Jennifer H Cooperrider, Ben A Derman, Andrzej J Jakubowiak
Journal: Blood
Blood (2023) 142 (Supplement 1): 4715.
https://doi.org/10.1182/blood-2023-189850
Published: 2023
Journal Articles

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

Clinical Trials & Observations
Jagoda K. Jasielec, Tadeusz Kubicki, Noopur Raje, Ravi Vij, Donna Reece, Jesus Berdeja, Benjamin A. Derman, Cara A. Rosenbaum, Paul Richardson, Sandeep Gurbuxani, Sarah Major, Brittany Wolfe, Andrew T. Stefka, Leonor Stephens, Kathryn M. Tinari, Tyler Hycner, Alexandra E. Rojek, Dominik Dytfeld, Kent A. Griffith, Todd M. Zimmerman, Andrzej J. Jakubowiak
Journal: Blood
Blood (2020) 136 (22): 2513–2523.
https://doi.org/10.1182/blood.2020007522
Published: 2020
Includes: Supplemental data